Search Results - "McLeod, L"

Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed by McLeod, Howard L.

“…The past decade has brought together substantial advances in human genome analysis and a maturation of understanding of tumor biology. Although there is much…”
Get full text

Drug treatments for covid-19: living systematic review and network meta-analysis by Siemieniuk, Reed AC, Bartoszko, Jessica J, Ge, Long, Zeraatkar, Dena, Izcovich, Ariel, Kum, Elena, Pardo-Hernandez, Hector, Qasim, Anila, Martinez, Juan Pablo Díaz, Rochwerg, Bram, Lamontagne, Francois, Han, Mi Ah, Liu, Qin, Agarwal, Arnav, Agoritsas, Thomas, Chu, Derek K, Couban, Rachel, Cusano, Ellen, Darzi, Andrea, Devji, Tahira, Fang, Bo, Fang, Carmen, Flottorp, Signe Agnes, Foroutan, Farid, Ghadimi, Maryam, Heels-Ansdell, Diane, Honarmand, Kimia, Hou, Liangying, Hou, Xiaorong, Ibrahim, Quazi, Khamis, Assem, Lam, Bonnie, Loeb, Mark, Marcucci, Maura, McLeod, Shelley L, Motaghi, Sharhzad, Murthy, Srinivas, Mustafa, Reem A, Neary, John D, Rada, Gabriel, Riaz, Irbaz Bin, Sadeghirad, Behnam, Sekercioglu, Nigar, Sheng, Lulu, Sreekanta, Ashwini, Switzer, Charlotte, Tendal, Britta, Thabane, Lehana, Tomlinson, George, Turner, Tari, Vandvik, Per O, Vernooij, Robin WM, Viteri-García, Andrés, Wang, Ying, Yao, Liang, Ye, Zhikang, Guyatt, Gordon H, Brignardello-Petersen, Romina

“…AbstractObjectiveTo compare the effects of treatments for coronavirus disease 2019 (covid-19).DesignLiving systematic review and network meta-analysis.Data…”
Get full text

The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update by Ramsey, L B, Johnson, S G, Caudle, K E, Haidar, C E, Voora, D, Wilke, R A, Maxwell, W D, McLeod, H L, Krauss, R M, Roden, D M, Feng, Q, Cooper-DeHoff, R M, Gong, L, Klein, T E, Wadelius, M, Niemi, M

“…Simvastatin is among the most commonly used prescription medications for cholesterol reduction. A single coding single‐nucleotide polymorphism, rs4149056T>C,…”
Get full text

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update by Amstutz, Ursula, Henricks, Linda M., Offer, Steven M., Barbarino, Julia, Schellens, Jan H.M., Swen, Jesse J., Klein, Teri E., McLeod, Howard L., Caudle, Kelly E., Diasio, Robert B., Schwab, Matthias

“…The purpose of this guideline is to provide information for the interpretation of clinical dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the…”
Get full text

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy by Moriyama, B, Obeng, A Owusu, Barbarino, J, Penzak, SR, Henning, SA, Scott, SA, Agúndez, JAG, Wingard, JR, McLeod, HL, Klein, TE, Cross, SJ, Caudle, KE, Walsh, TJ

“…Voriconazole, a triazole antifungal agent, demonstrates wide interpatient variability in serum concentrations, due in part to variant CYP2C19 alleles…”
Get full text

Genomic medicine: a decade of successes, challenges, and opportunities by McCarthy, Jeanette J, McLeod, Howard L, Ginsburg, Geoffrey S

“…Genomic medicine--an aspirational term 10 years ago--is gaining momentum across the entire clinical continuum from risk assessment in healthy individuals to…”
Get more information

Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study by Gillis, Nancy K, PharmD, Ball, Markus, PhD, Zhang, Qing, MD, Ma, Zhenjun, PhD, Zhao, YuLong, PhD, Yoder, Sean J, MS, Balasis, Maria E, BS, Mesa, Tania E, BS, Sallman, David A, MD, Lancet, Jeffrey E, Prof, Komrokji, Rami S, Prof, List, Alan F, Prof, McLeod, Howard L, Prof, Alsina, Melissa, Prof, Baz, Rachid, MD, Shain, Kenneth H, MD, Rollison, Dana E, PhD, Padron, Eric, Dr

“…Summary Background Clonal haemopoiesis of indeterminate potential (CHIP) is an age-associated genetic event linked to increased risk of primary haematological…”
Get full text

Defibrillation Strategies for Refractory Ventricular Fibrillation by Cheskes, Sheldon, Verbeek, P. Richard, Drennan, Ian R., McLeod, Shelley L., Turner, Linda, Pinto, Ruxandra, Feldman, Michael, Davis, Matthew, Vaillancourt, Christian, Morrison, Laurie J., Dorian, Paul, Scales, Damon C.

“…In a trial involving patients with refractory ventricular fibrillation, double sequential external defibrillation or vector-change defibrillation improved…”
Get full text

Platinum neurotoxicity pharmacogenetics by McWhinney, Sarah R, Goldberg, Richard M, McLeod, Howard L

“…Cisplatin, carboplatin, and oxaliplatin anticancer drugs are commonly used to treat lung, colorectal, ovarian, breast, head and neck, and genitourinary…”
Get full text

CYP2D6 and tamoxifen: DNA matters in breast cancer by McLeod, Howard L, Hoskins, Janelle M, Carey, Lisa A

“…Key Points The selective oestrogen receptor modulator tamoxifen is the most widely used antioestrogen for the treatment of hormone-dependent breast cancer…”
Get full text

The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy by Wilke, R A, Ramsey, L B, Johnson, S G, Maxwell, W D, McLeod, H L, Voora, D, Krauss, R M, Roden, D M, Feng, Q, Cooper-DeHoff, R M, Gong, L, Klein, T E, Wadelius, M, Niemi, M

“…Cholesterol reduction from statin therapy has been one of the greatest public health successes in modern medicine. Simvastatin is among the most commonly used…”
Get full text

The role of organisational support in teleworker wellbeing: A socio-technical systems approach by Bentley, T.A., Teo, S.T.T., McLeod, L., Tan, F., Bosua, R., Gloet, M.

“…The prevalence of telework and other forms of mobile working enabled by digital technology is increasing markedly. Following a socio-technical systems…”
Get full text

PI3K/Akt/mTOR pathway as a target for cancer therapy by Morgensztern, Daniel, McLeod, Howard L

“…The PI3K/Akt/mTOR pathway regulates several normal cellular functions that are also critical for tumorigenesis, including cellular proliferation, growth,…”
Get full text

The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy by Knepper, Todd C, Montesion, Meagan, Russell, Jeffery S, Sokol, Ethan S, Frampton, Garrett M, Miller, Vincent A, Albacker, Lee A, McLeod, Howard L, Eroglu, Zeynep, Khushalani, Nikhil I, Sondak, Vernon K, Messina, Jane L, Schell, Michael J, DeCaprio, James A, Tsai, Kenneth Y, Brohl, Andrew S

“…Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous malignancy, which has demonstrated sensitivity to immune checkpoint inhibitor therapy. Here, we…”
Get full text

Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin by Gage, BF, Eby, C, Johnson, JA, Deych, E, Rieder, MJ, Ridker, PM, Milligan, PE, Grice, G, Lenzini, P, Rettie, AE, Aquilante, CL, Grosso, L, Marsh, S, Langaee, T, Farnett, LE, Voora, D, Veenstra, DL, Glynn, RJ, Barrett, A, McLeod, HL

“…Initiation of warfarin therapy using trial‐and‐error dosing is problematic. Our goal was to develop and validate a pharmacogenetic algorithm. In the derivation…”
Get full text

Placing marine protected areas onto the ecosystem-based management seascape by Halpern, Benjamin S., Lester, Sarah E., McLeod, Karen L., Gaines, Steven D.

“…The rapid increase in the science and implementation of marine protected areas (MPAs) around the world in the past 15 years is now being followed by similar…”
Get full text

UGT1A128 Genotype and Irinotecan-Induced Neutropenia: Dose Matters by Hoskins, Janelle M., Goldberg, Richard M., Qu, Pingping, Ibrahim, Joseph G., McLeod, Howard L.

“…The Food and Drug Administration and Pfizer changed the package insert for irinotecan to include a patient's UGT1A1*28 genotype as a risk factor for severe…”
Get full text

Prophylaxis against covid-19: living systematic review and network meta-analysis by Bartoszko, Jessica J, Siemieniuk, Reed A C, Kum, Elena, Qasim, Anila, Zeraatkar, Dena, Martinez, Juan Pablo Diaz, Azab, Maria, Ibrahim, Sara, Izcovich, Ariel, Soto, Gonzalo Bravo, Roldan, Yetiani, Agarwal, Arnav, Agoritsas, Thomas, Chu, Derek K, Couban, Rachel, Devji, Tahira, Foroutan, Farid, Ghadimi, Maryam, Honarmand, Kimia, Khamis, Assem, Lamontagne, Francois, Loeb, Mark, McLeod, Shelley L, Motaghi, Sharhzad, Murthy, Srinivas, Mustafa, Reem A, Rochwerg, Bram, Switzer, Charlotte, Thabane, Lehana, Vandvik, Per O, Vernooij, Robin W M, Wang, Ying, Yao, Liang, Guyatt, Gordon H, Brignardello-Petersen, Romina

“…This is the second version (first update) of the living systematic review, replacing the previous version (available as a data supplement). When citing this…”
Get more information

Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects by Evans, William E, McLeod, Howard L

“…It is well recognized that different patients respond in different ways to the same medication. These differences are often greater among members of a…”
Get full text

Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing by Caudle, K E, Thorn, C F, Klein, T E, Swen, J J, McLeod, H L, Diasio, R B, Schwab, M

“…The fluoropyrimidines are the mainstay chemotherapeutic agents for the treatment of many types of cancers. Detoxifying metabolism of fluoropyrimidines requires…”
Get full text